Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...
The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...
STIMVIA, a neuromodulation company focused on transforming the treatment of bladder dysfunction, today announced the appointment of Russ Mably as Chief Executive Officer. Mably will lead the company through its next phase of international growth, expanding access to STIMVIA's personalised...
Wellspect have been innovators in catheterisation since developing the world’s first hydrophilic catheter. Now the Swedish company look to revolutionise the way women learn and perform intermittent self-catheterisation (ISC).
Targeting urologists and oncologists - for focus groups to be held after 31 July 2026 Do you support patients with low or intermediate-risk prostate cancer? Researchers from the University of Southampton are inviting urologists and oncologists to help refine an...
In the third article in this series the authors describe their experience with the very rare indications for laparoscopic stone surgery. Case 1 A 44-year-old woman presented with several months of malaise and right flank pain. A CT scan demonstrated...
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would write about a particular artefact...
Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...
This is a multicentre study from Europe. The female genitals and lower urinary tract have a common embryological origin arising from urogenital sinus. Therefore, both could be sensitive to female sex steroid hormones. Oestrogens and progesterone receptors have been demonstrated...
4 March 2025
| Javier Angulo (Prof), Jonathan Charles Goddard
|
URO - Technology
In this series of articles, I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). Does the name Joaquín Albarrán mean anything to you? Maybe you remember using...
Introduction Benign prostatic hyperplasia (BPH), a common condition associated with ageing, affects 50% of those between the ages of 50 and 60 years, and as many as 90% of those older than 80 years. BPH is characterised by unregulated, benign...